Harvard Business Review
OCTOBER 26, 2011
Between 2006 and 2008, more than $1 billion venture-capital dollars were channeled into startups focused on solar, wind and biofuel technologies. Their behavior displays promising parallels to the early days of the biotechnology industry.
Harvard Business Review
FEBRUARY 22, 2013
Cephalon's IPO was in 1991, part of the second wave of biotechnology companies to sell shares to the public. Baldino moved aggressively to bring Provigil to market. Baldino sought to convince thought leaders of the therapeutic benefit, prove the drug worked, and then market it to the needy community. By 2010, sales exceeded $2B.
Expert insights. Personalized for you.
11 
Let's personalize your content